These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33621163)

  • 21. Recent advances in the treatment and management of excessive daytime sleepiness.
    Black J; Duntley SP; Bogan RK; O'Malley MB
    CNS Spectr; 2007 Feb; 12(2 Suppl 2):1-14; quiz 15. PubMed ID: 17277717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Modafinil and Armodafinil in Patients With Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials.
    Kuan YC; Wu D; Huang KW; Chi NF; Hu CJ; Chung CC; Tam KW; Huang YH
    Clin Ther; 2016 Apr; 38(4):874-88. PubMed ID: 26923035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sleep-Disordered Breathing and Excessive Daytime Sleepiness.
    He K; Kapur VK
    Sleep Med Clin; 2017 Sep; 12(3):369-382. PubMed ID: 28778235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual excessive daytime sleepiness in patients with obstructive sleep apnea treated with positive airway pressure therapy.
    Foster SN; Hansen SL; Scalzitti NJ; Matsangas P; Moore BA; Mysliwiec V
    Sleep Breath; 2020 Mar; 24(1):143-150. PubMed ID: 30953233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC; Guilleminault C
    Expert Rev Respir Med; 2018 Dec; 12(12):1007-1019. PubMed ID: 30365900
    [No Abstract]   [Full Text] [Related]  

  • 26. The cholinergic system may play a role in the pathophysiology of residual excessive sleepiness in patients with obstructive sleep apnea.
    Otuyama LJ; Rizzi CF; Piovezan RD; Werli KS; Brasil EL; Sukys-Claudino L; Tufik S; Poyares D
    Med Hypotheses; 2013 Sep; 81(3):509-11. PubMed ID: 23891038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
    Singh H; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Thorpy MJ
    Adv Ther; 2022 Sep; 39(9):4359-4373. PubMed ID: 35927541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure.
    Inoue Y; Miki M; Tabata T
    Sleep Med; 2016; 27-28():45-48. PubMed ID: 27938918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP.
    Bogan RK; Maynard JP; Neuwirth R; Faessel H; Swick T; Olsson T
    Sleep Med; 2023 Jul; 107():229-235. PubMed ID: 37244138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual excessive daytime sleepiness in patients with sleep apnea syndrome receiving continuous positive airway pressure in Japan: A single-center study.
    Hamada S; Togawa J; Sunadome H; Nagasaki T; Takahashi N; Hirai T; Sato S
    Respir Investig; 2023 Sep; 61(5):541-547. PubMed ID: 37331123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for residual excessive sleepiness and cognition in CPAP-treated patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis.
    Avellar AB; Carvalho LB; Prado GF; Prado LB
    Sleep Med Rev; 2016 Dec; 30():97-107. PubMed ID: 27865102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
    Inoue Y; Takasaki Y; Yamashiro Y
    J Clin Sleep Med; 2013 Aug; 9(8):751-7. PubMed ID: 23946704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA.
    Badran M; Puech C; Barrow MB; Runion AR; Gozal D
    Sleep Med; 2023 Jul; 107():89-99. PubMed ID: 37137196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parameters affecting improvement of excessive daytime sleepiness in obstructive sleep apnea patients.
    Park SH; Bae WY; Kim S; Kim YG; Yun YB; Lee HG; Kim BJ; Kim JH
    Am J Otolaryngol; 2023; 44(1):103683. PubMed ID: 36323161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obstructive sleep apnea (OSA) and excessive sleepiness associated with OSA: recognition in the primary care setting.
    Lieberman JA
    Postgrad Med; 2009 Jul; 121(4):33-41. PubMed ID: 19641266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
    Chapman JL; Kempler L; Chang CL; Williams SC; Sivam S; Wong KK; Yee BJ; Grunstein RR; Marshall NS
    Thorax; 2014 Mar; 69(3):274-9. PubMed ID: 24287166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
    Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obstructive sleep apnea and self-reported functional impairment in revascularized patients with coronary artery disease in the RICCADSA trial.
    Baniak LM; Chasens ER; Luyster FS; Strollo PJ; Thunström E; Peker Y
    Sleep Breath; 2018 Dec; 22(4):1169-1177. PubMed ID: 30324547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK; Mayer G; Rosenberg R; Malhotra A; Zammit GK; Gotfried M; Chandler P; Baladi M; Strohl KP
    Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.